E. Boven
- Oncology top 5%
- Cancer Treatment and Pharmacology 6
- Drug Transport and Resistance Mechanisms 5
- Colorectal Cancer Treatments and Studies 4
- Lung Cancer Research Studies 3
- Geriatrics and Gerontology top 5%
- Family Practice top 10%
- Toxicology top 10%
- Pharmacology top 10%
-
- Cancer therapeutics and mechanisms 4
-
- Renal cell carcinoma treatment 3
-
- Pharmacological Effects and Toxicity Studies 3
-
- Radiomics and Machine Learning in Medical Imaging 2
- Co-authors
- Herbert M. PinedoGiuseppe GiacconeH.E. GallW J van der VijghK. MrossPaul A. MaessenBoudewijn J.M. BraakhuisGodefridus J. Peters
- Journals
- Journal of Clinical Oncology (4 papers)Annals of Oncology (4 papers)International Journal of Cancer (3 papers)
- Partner nations
- NetherlandsUnited KingdomBelgium
In The Last Decade
E. Boven
25 papers receiving 742 citations
Peers
Comparison fields: 5 of 80
- Oncology 503
- Geriatrics and Gerontology 58
- Family Practice 24
- Toxicology 31
- Pharmacology 57
Countries citing papers authored by E. Boven
This map shows the geographic impact of E. Boven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Boven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Boven more than expected).
Fields of papers citing papers by E. Boven
This network shows the impact of papers produced by E. Boven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Boven. The network helps show where E. Boven may publish in the future.
Co-authorship network
The 25 scholars most cited alongside E. Boven, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 1 | |
| 2 | 2011 | 103 | |
| 3 | 2010 | 1 | |
| 4 | PHASE I STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SARACATINIB (AZD0530) PLUS CARBOPLATIN (C) AND/OR PACLITAXEL (P) IN PATIENTS WITH SOLID TUMOURS | 2010 | 1 |
| 5 | 2009 | 7 | |
| 6 | 2009 | 2 | |
| 7 | 2007 | 2 | |
| 8 | FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer. | 2004 | 2 |
| 9 | 1999 | 2 | |
| 10 | Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. | 1999 | 39 |
| 11 | 1998 | 81 | |
| 12 | 1998 | 47 | |
| 13 | 1997 | 3 | |
| 14 | 1997 | 103 | |
| 15 | 1997 | 15 | |
| 16 | 1995 | 18 | |
| 17 | 1995 | 9 | |
| 18 | 1994 | 10 | |
| 19 | [The hematopoietic growth factor GM-CSF in chemotherapy for advanced breast carcinoma]. | 1991 | 4 |
| 20 | 1988 | 156 |
About E. Boven
E. Boven is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine, having authored 25 papers that have together received 770 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), Drug Transport and Resistance Mechanisms (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Cancer therapeutics and mechanisms (4 papers), Renal cell carcinoma treatment (3 papers), Lung Cancer Research Studies (3 papers), Pharmacological Effects and Toxicity Studies (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). The work is most often cited by research in Oncology (503 citations), Geriatrics and Gerontology (58 citations) and Family Practice (24 citations). E. Boven has collaborated with scholars based in Netherlands, United Kingdom and Belgium. Frequent co-authors include Herbert M. Pinedo, Giuseppe Giaccone, H.E. Gall, W J van der Vijgh, K. Mross, Paul A. Maessen, Boudewijn J.M. Braakhuis, Godefridus J. Peters, Veronique W.T. Ruiz van Haperen and G. Veerman. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, International Journal of Cancer, British Journal of Cancer and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.